Mirum Pharmaceuticals
NASDAQ · MIRM·Foster City, CA·Small-cap·Approved
Commercial-stage biopharma focused on rare and orphan diseases. LIVMARLI (maralixibat) and CHENODAL approved for cholestatic liver diseases (Alagille syndrome, PFIC) and CTX. Pipeline includes volixibat for primary biliary cholangitis and primary sclerosing cholangitis.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Mirum Corporate Presentation April 2026 | Corporate overview | April 15, 2026 | 63 |